Citius Pharmaceuticals, Inc.: 10-Q filed 2019-05-15
What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2019-05-15 (fiscal Q2 2019): 26 published measures, 76 facts as tagged in accession 0001213900-19-008833.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-05-15
- Fiscal period
- fiscal Q2 2019
- Accession
- 0001213900-19-008833 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 24,235,696 | USD | |
| At 2018-09-30 | 31,050,524 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 20,874,685 | USD | |
| At 2018-12-31 | 24,178,203 | USD | |
| At 2018-09-30 | 27,865,684 | USD | |
| At 2018-03-31 | 23,501,706 | USD | |
| At 2017-12-31 | 25,856,314 | USD | |
| At 2017-09-30 | 21,947,388 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 3,199,097 | USD | |
| At 2018-09-30 | 9,184,003 | USD | |
| At 2018-03-31 | 5,007,865 | USD | |
| At 2017-09-30 | 3,204,108 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -3,631,929 | USD | 90 |
| 2018-10-01 to 2019-03-31 | -7,506,659 | USD | 182 |
| 2018-01-01 to 2018-03-31 | -4,421,650 | USD | 90 |
| 2017-10-01 to 2018-03-31 | -7,667,816 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-03-31 | -6,008,122 | USD | 182 |
| 2017-10-01 to 2018-03-31 | -6,567,490 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-03-31 | 23,216 | USD | 182 |
| 2017-10-01 to 2018-03-31 | 8,371,247 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | -47,764,497 | USD | |
| At 2018-09-30 | -40,257,838 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 1,013 | USD | |
| At 2018-09-30 | 1,483 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 203,695 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 374,944 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 214,666 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 504,687 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -3,641,968 | USD | 90 |
| 2018-10-01 to 2019-03-31 | -7,514,442 | USD | 182 |
| 2018-01-01 to 2018-03-31 | -4,866,944 | USD | 90 |
| 2017-10-01 to 2018-03-31 | -8,109,726 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 3,245,720 | USD | |
| At 2018-09-30 | 10,060,078 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 4,105 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 8,108 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 4,706 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 8,090 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 3,361,011 | USD | |
| At 2018-09-30 | 3,184,840 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 1,926,086 | USD | |
| At 2018-09-30 | 1,573,444 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 1,586,796 | USD | |
| At 2018-09-30 | 1,586,796 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 3,641,968 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 7,514,442 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 4,866,944 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 8,109,726 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 1,699,876 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 3,812,977 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 3,439,853 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 4,046,374 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 18,645,360 | shares | |
| At 2018-09-30 | 16,198,791 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 68,620,537 | USD | |
| At 2018-09-30 | 68,107,323 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 175,993 | USD | |
| At 2018-09-30 | 181,657 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -3,631,929 | USD | 90 |
| 2018-10-01 to 2018-12-31 | -3,874,730 | USD | 92 |
| 2018-01-01 to 2018-03-31 | -4,421,650 | USD | 90 |
| 2017-10-01 to 2017-12-31 | -3,246,166 | USD | 92 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 1,738,397 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 3,326,521 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 1,212,425 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 3,558,665 | USD | 182 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-03-31 | 470 | USD | 182 |
| 2017-10-01 to 2018-03-31 | 1,283 | USD | 182 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 10,039 | USD | 90 |
| 2018-10-01 to 2019-03-31 | 7,783 | USD | 182 |
| 2018-01-01 to 2018-03-31 | 445,294 | USD | 90 |
| 2017-10-01 to 2018-03-31 | 441,910 | USD | 182 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-03-31 | 5 | USD | 182 |
| 2017-10-01 to 2018-03-31 | 193 | USD | 182 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-03-31 | 352,642 | USD | 182 |
| 2017-10-01 to 2018-03-31 | 798,042 | USD | 182 |
Inspect the source
- Entity
- Citius Pharmaceuticals, Inc. / CIK 0001506251
- Captured
- 2026-09-20T09:12:24.553Z
- SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))